Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.
No longer availableNCT04604288
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is an Individual Patient Expanded Access IND of autologous adipose derived Mesenchymal Stem Cells with the primary goal of treating 1 individual with bilateral knee pain who has exhausted all treatment options, his condition has not improved, and his quality of life is severely affected by the condition. There are no FDA approved, fully restorative treatments for his condition. The subject will receive 2 autologous HB-adMSCs intravenous infusion of 200 million (2 x 10\^8 cells) total cells, and 4 autologous HB-adMSCs intra-articular injections (1 in each knee joint/ intervention).
Study details
- Official title
- Individual Patient Expanded Access IND to Evaluate the Safety and Preliminary Efficacy of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.
- Conditions
- Interventions
- Biological: HB-adMSC
- Sponsor
- Hope Biosciences Research Foundation
- Sex
- All
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria 1. Documented diagnosis of bilateral knee pain. 2. Hemodynamically stable. Exclusion Criteria 1. Immunosuppression as defined by WBC \< 3, 000 cells/ml at baseline screening. 2. Subjects with pro-coagulant disease processes such as Factor V Leiden deficiency, Factor C and S deficiency, anti-thrombin deficiency, prothrombin mutation, and dysfibrinogenemia. 3. Subjects with abnormal vital signs, abnormal liver or kidney function, and hematological abnormalities specifically: 1. BP systolic: \>160 or \<100 mmHg, DBP: \>100 SBP or \<50mmHg 2. Pulse: \<60 or \>105 bpm 3. Respiratory Rate: \<9 and \>25 breaths per minute 4. Temperature: \>99.9 degrees Fahrenheit 5. O2 saturation: \<92% 6. Liver enzymes \>2x upper limit of normal (ULN) 7. Abnormal bilirubin unless due to benign unconjugated hyperbilirubinemia 8. eGFR \<60 mL/min/ 1.73 m2 by CKD-EPI 9. HbA1C \>9% 10. Hb \<10 mg/dL 11. Platelet Count \<100,000 4. Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSCs administration. 5. Any abnormal, inexplicable laboratory result with no obvious cause defined. 6. Participation in other interventional research studies. 7. Unwillingness to return for follow-up visits.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04604288